CryoPort Stock News

CryoPort, Inc. (CYRX) delivered earnings and revenue surprises of -14.29% and 4.10%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Cryoport has been punished over the last 12 months amid a number of downside catalysts. Shares have recently curled up off 52-week lows, asking the question on whether this is an appropriate time for

Despite macroeconomic concerns, Cryoport is still generating a 7% revenue growth for the quarter. The new Houston facility that is in collaboration with Takeda would start generating sales as soon as

Cryoport, Inc. (NASDAQ:CYRX ) Q3 2022 Results Conference Call November 3, 2022 5:00 PM ET Company Participants Todd Fromer - Managing Partner-KCSA Jerrell Shelton - Chief Executive Officer Robert Stef

CryoPort, Inc. (CYRX) delivered earnings and revenue surprises of -15.38% and 13.89%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

CryoPort, Inc. (CYRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near te

As a small logistic operator servicing other celllular therapy innovators, CryoPort is powered by the prudent merger/acquisition growth approach. Regardless of the bear market, CryoPort has been enjoy

Cryoport, Inc. (NASDAQ:CYRX ) Q2 2022 Earnings Conference Call August 4, 2022 5:00 PM ET Company Participants Todd Fromer – Managing Partner-KCSA Jerrell Shelton – Chief Executive Officer Tom Hein

Biopharmaceutical stocks have undergone a dramatic correction over the past six months, with the XBI declining by 45%. I highlight stocks that are attractively priced.

Cryoport is not just any biotech company, as it is banking on the booming logistic businesses for the cell/gene therapy sector. Leveraging the powerful merger and acquisition approach, Cryoport has be

Cryoport, Inc. (NASDAQ:CYRX ) Q1 2022 Earnings Conference Call May 5, 2022 5:00 PM ET Company Participants Todd Fromer - President, KCSA Strategic Communications Jerrell Shelton - CEO Robert Stefanovi

Over the past 3 months, 5 analysts have published their opinion on CryoPort (NASDAQ:CYRX) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a compan

CryoPort, Inc. (CYRX) delivered earnings and revenue surprises of -55% and 0.63%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Being a logistics service provider for the booming cell/gene therapy sector, Cryoport is enjoying the robust industry tailwind and thereby positioning itself to be an investment bonanza. Various acqui

Cryoport: Risky Investment With Upside Potential